Literature DB >> 18981717

New insights into the role of CXCR4 in prostate cancer metastasis.

Candece L Gladson1, Danny R Welch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18981717      PMCID： PMC2891934          DOI： 10.4161/cbt.7.11.7218

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN： 1538-4047            Impact factor:   4.742


× No keyword cloud information.
  16 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

2.  CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12.

Authors:  Sreenivasa R Chinni; Sivasakthy Sivalogan; Zhong Dong; J Carlos Trindade Filho; Xiyun Deng; R Daniel Bonfil; Michael L Cher
Journal:  Prostate       Date:  2006-01-01       Impact factor: 4.104

3.  CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins.

Authors:  Tobias Engl; Borna Relja; Dana Marian; Christa Blumenberg; Iris Müller; Wolf-Dietrich Beecken; Jon Jones; Eva M Ringel; Jürgen Bereiter-Hahn; Dietger Jonas; Roman A Blaheta
Journal:  Neoplasia       Date:  2006-04       Impact factor: 5.715

4.  Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells.

Authors:  Yan-Xi Sun; Ming Fang; Jianhua Wang; Carlton R Cooper; Kenneth J Pienta; Russell S Taichman
Journal:  Prostate       Date:  2007-01-01       Impact factor: 4.104

5.  Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation.

Authors:  Promil Kukreja; Asim B Abdel-Mageed; Debasis Mondal; Kai Liu; Krishna C Agrawal
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

6.  Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo.

Authors:  Yan-Xi Sun; Abraham Schneider; Younghun Jung; Jianhua Wang; Jinlu Dai; Jingcheng Wang; Kevin Cook; Nadir I Osman; Amy J Koh-Paige; Hyusuk Shim; Kenneth J Pienta; Evan T Keller; Laurie K McCauley; Russell S Taichman
Journal:  J Bone Miner Res       Date:  2004-11-16       Impact factor: 6.741

7.  CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12.

Authors:  Yan-Xi Sun; Elisabeth A Pedersen; Yusuke Shiozawa; Aaron M Havens; Younghun Jung; Jingcheng Wang; Kenneth J Pienta; Russell S Taichman
Journal:  Clin Exp Metastasis       Date:  2008-06-18       Impact factor: 5.150

8.  CXCL12-CXCR4 interactions modulate prostate cancer cell migration, metalloproteinase expression and invasion.

Authors:  Shailesh Singh; Udai P Singh; William E Grizzle; James W Lillard
Journal:  Lab Invest       Date:  2004-12       Impact factor: 5.662

9.  Osteoblast-conditioned media influence the expression of E-selectin on bone-derived vascular endothelial cells.

Authors:  Lauren A Makuch; Donna M Sosnoski; Carol V Gay
Journal:  J Cell Biochem       Date:  2006-08-01       Impact factor: 4.429

10.  Tumor cell-specific blockade of CXCR4/SDF-1 interactions in prostate cancer cells by hTERT promoter induced CXCR4 knockdown: A possible metastasis preventing and minimizing approach.

Authors:  Yifei Xing; Mei Liu; Yuefeng Du; Feng Qu; Yangsheng Li; Qingwei Zhang; Yajun Xiao; Jun Zhao; Fuqing Zeng; Chuanguo Xiao
Journal:  Cancer Biol Ther       Date:  2008-11-26       Impact factor: 4.742
View more
  17 in total

1.  Gossypol inhibits growth, invasiveness, and angiogenesis in human prostate cancer cells by modulating NF-κB/AP-1 dependent- and independent-signaling.

Authors:  Jiahua Jiang; Veronika Slivova; Andrej Jedinak; Daniel Sliva
Journal:  Clin Exp Metastasis       Date:  2011-12-14       Impact factor: 5.150

Review 2.  Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature.

Authors:  Angus Dalgleish; Peter Featherstone; Viatcheslav Vlassov; Moshe Rogosnitzky
Journal:  Invest New Drugs       Date:  2014-01-18       Impact factor: 3.850

Review 3.  The functional role of reactive stroma in benign prostatic hyperplasia.

Authors:  Isaiah G Schauer; David R Rowley
Journal:  Differentiation       Date:  2011-06-12       Impact factor: 3.880

Review 4.  Metastasis suppressor genes at the interface between the environment and tumor cell growth.

Authors:  Douglas R Hurst; Danny R Welch
Journal:  Int Rev Cell Mol Biol       Date:  2011       Impact factor: 6.813

Review 5.  Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer.

Authors:  Isaiah G Schauer; Anil K Sood; Samuel Mok; Jinsong Liu
Journal:  Neoplasia       Date:  2011-05       Impact factor: 5.715

6.  Role of Chemokines and Chemokine Receptors in Prostate Cancer Development and Progression.

Authors:  Rajendra K Singh; Akulapalli Sudhakar; Bal L Lokeshwar
Journal:  J Cancer Sci Ther       Date:  2010

Review 7.  Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors:  Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal:  Antioxid Redox Signal       Date:  2014-01-22       Impact factor: 8.401

Review 8.  The intricate role of CXCR4 in cancer.

Authors:  Samit Chatterjee; Babak Behnam Azad; Sridhar Nimmagadda
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

Review 9.  At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.

Authors:  Gary D Luker; Jinming Yang; Ann Richmond; Stefania Scala; Claudio Festuccia; Margret Schottelius; Hans-Jürgen Wester; Johann Zimmermann
Journal:  J Leukoc Biol       Date:  2020-10-26       Impact factor: 4.962

Review 10.  Small molecule inhibitors of CXCR4.

Authors:  Bikash Debnath; Shili Xu; Fedora Grande; Antonio Garofalo; Nouri Neamati
Journal:  Theranostics       Date:  2013-01-15       Impact factor: 11.556
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.